A 62-year-old woman completed adjuvant dose-dense AC-paclitaxel and trastuzumab for HER2-positive breast cancer. She develops heart failure symptoms

Question

A 62-year-old woman completed adjuvant dose-dense AC-paclitaxel and trastuzumab for HER2-positive breast cancer. She develops heart failure symptoms 6 months after completing trastuzumab. LVEF is 35%. What is the typical reversibility of trastuzumab-related cardiac dysfunction compared with anthracycline-induced cardiomyopathy?

Accepted Answer

Trastuzumab cardiotoxicity is typically reversible with heart failure treatment and drug cessation

Answer

Both are always fully reversible as the preferred next management strategy in this patient

Answer

Neither causes cardiac dysfunction as the preferred next management strategy in this patient

Answer

Both are irreversible as the preferred next management strategy in this patient

Answer

Anthracycline cardiomyopathy is reversible as the preferred next management strategy

Cardiotoxicity — SCE Medical Oncology MCQ